drugset / Trial / NCT03935295

Dysport ® as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis

NCT03935295 ↗

Phase 4 Recruiting 90 enrolled Johns Hopkins University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the combined effect of botulinum toxin A (administered as Dysport® (Ipsen Pharmaceuticals)) and bracing in children with adolescent idiopathic scoliosis. Two thirds of patients will be treated with Dysport® and bracing, while the remaining patients will be treated with placebo and bracing.

Timeline

Start
2020-09-03
Primary completion
2026-12-31
Completion
2026-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 1000 iu Intramuscular